Shares of Achaogen Inc (NASDAQ:AKAO) have been given an average rating of “Hold” by the fourteen research firms that are presently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and eight have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $16.76.

A number of equities research analysts have recently commented on the company. Stifel Nicolaus lifted their target price on Achaogen from $14.00 to $22.00 and gave the stock a “buy” rating in a research note on Tuesday, August 7th. BidaskClub cut Achaogen from a “sell” rating to a “strong sell” rating in a research note on Wednesday, July 18th. Needham & Company LLC cut Achaogen from a “buy” rating to a “hold” rating in a research note on Tuesday, August 7th. SunTrust Banks lowered their target price on Achaogen from $16.00 to $10.00 and set a “buy” rating on the stock in a research note on Monday, August 20th. Finally, Zacks Investment Research upgraded Achaogen from a “sell” rating to a “hold” rating in a research note on Friday, August 3rd.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. increased its holdings in Achaogen by 2.1% in the 1st quarter. BlackRock Inc. now owns 2,898,459 shares of the biopharmaceutical company’s stock worth $37,536,000 after acquiring an additional 60,613 shares during the last quarter. Prosight Management LP increased its holdings in Achaogen by 15.8% in the 1st quarter. Prosight Management LP now owns 661,054 shares of the biopharmaceutical company’s stock worth $8,561,000 after acquiring an additional 90,134 shares during the last quarter. UBS Group AG increased its holdings in Achaogen by 681.5% in the 1st quarter. UBS Group AG now owns 297,632 shares of the biopharmaceutical company’s stock worth $3,854,000 after acquiring an additional 259,546 shares during the last quarter. Candriam Luxembourg S.C.A. increased its holdings in Achaogen by 29.0% in the 1st quarter. Candriam Luxembourg S.C.A. now owns 222,555 shares of the biopharmaceutical company’s stock worth $2,882,000 after acquiring an additional 50,000 shares during the last quarter. Finally, Gabelli Funds LLC increased its holdings in Achaogen by 18.6% in the 2nd quarter. Gabelli Funds LLC now owns 206,400 shares of the biopharmaceutical company’s stock worth $1,787,000 after acquiring an additional 32,400 shares during the last quarter. 60.61% of the stock is owned by institutional investors.

NASDAQ:AKAO traded up $0.16 during trading hours on Wednesday, hitting $4.36. 25,631 shares of the company traded hands, compared to its average volume of 851,615. The company has a current ratio of 3.79, a quick ratio of 3.79 and a debt-to-equity ratio of 0.42. Achaogen has a one year low of $4.06 and a one year high of $16.49. The stock has a market cap of $189.88 million, a PE ratio of -1.33 and a beta of 0.69.

Achaogen (NASDAQ:AKAO) last issued its quarterly earnings data on Monday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.92) by ($0.19). Achaogen had a negative net margin of 2,286.21% and a negative return on equity of 146.50%. The company had revenue of $2.56 million for the quarter, compared to the consensus estimate of $1.49 million. sell-side analysts forecast that Achaogen will post -3.78 earnings per share for the current fiscal year.

About Achaogen

Achaogen, Inc, a late-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae.

Recommended Story: Earnings Per Share

Analyst Recommendations for Achaogen (NASDAQ:AKAO)

Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.